Anti-VSIG4 Monoclonal Antibody Binding Both Protein Forms
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-VSIG4 antibodies only bind one form of the protein, leading to partial inhibition of VSIG4 activity and lack application in cancer treatment, as they do not effectively suppress VSIG4-mediated anti-inflammatory signals or revert inhibition of T-cell activation.
Innovation Solution
Development of a monoclonal antibody specifically binding to both long and short forms of VSIG4, with specific heavy-chain and light-chain complementarity-determining regions (CDRs) sequences, to efficiently suppress VSIG4-mediated anti-inflammatory signals and repolarize tumor-associated macrophages to a tumour suppressive M1 phenotype, thereby activating an immune response and conferring protective anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-VSIG4 antibodies are used, then they can bind to VSIG4 protein, but they only bind one form of the protein (long or short form) leading to partial inhibition of VSIG4 activity
Solution Approach 1:
The patent develops a monoclonal antibody (designated as antibody or antigen-binding fragment thereof) that universally binds to both the long form and short form of VSIG4 protein. This universal binding capability allows the antibody to effectively inhibit VSIG4-mediated anti-inflammatory signals regardless of which form is present, thereby achieving complete functional inhibition rather than partial inhibition.
Solution Approach 2:
The patent identifies and utilizes specific complementarity-determining region (CDR) sequences in the antibody variable regions that enable recognition and binding to both VSIG4 forms. By optimizing the CDR sequences (particularly CDR-H3 and CDR-L3), the antibody achieves enhanced affinity and specificity for both protein forms, transforming the binding parameter to accommodate multiple targets.
2Ease of manufacture
If current anti-VSIG4 antibodies are used, then they can be produced as immunotherapeutic agents, but they lack application in cancer treatment due to insufficient suppression of anti-inflammatory signals and T-cell activation inhibition
Solution Approach 1:
The patent optimizes the antibody's biological function by selecting specific CDR sequences that enhance its ability to block VSIG4-mediated immune suppression. This parameter optimization ensures the antibody can effectively suppress anti-inflammatory signals and reverse T-cell activation inhibition, meeting the therapeutic requirements for cancer treatment while maintaining manufacturability.
Solution Approach 2:
The patent provides a complete antibody sequence specification including variable and constant regions, enabling straightforward recombinant production. This detailed sequence information allows for efficient manufacturing of the therapeutic antibody without requiring complex production processes, making the drug development economically viable.
Data Source
AI summary
New anti-VSIG4 (V-set Ig domain-containing 4) antibodies or an antigen-binding fragments are disclosed. Uses of these antibodies, including methods of treatment, are also provided.